Hepatitis B immunoglobulin (HBIG) combined with long-term entecavir prophylaxis for hepatitis B virus infection in allogeneic hematopoietic stem cell transplantation with hepatitis B surface antigen-positive donors

Yaoyao Shen; Jiaqian Qi; Yi Wang; Jia Chen; Yi Fan; Ying Wang; Depei Wu; Yang Xu

doi:10.1080/10428194.2021.1901095

Hepatitis B immunoglobulin (HBIG) combined with long-term entecavir prophylaxis for hepatitis B virus infection in allogeneic hematopoietic stem cell transplantation with hepatitis B surface antigen-positive donors

Leuk Lymphoma. 2021 Sep;62(9):2284-2287. doi: 10.1080/10428194.2021.1901095. Epub 2021 Mar 18.

Authors

Yaoyao Shen^{1

2

3}, Jiaqian Qi^{1

2

3}, Yi Wang^{1

2

3}, Jia Chen^{1

2

3}, Yi Fan^{1

2

3}, Ying Wang^{1

2

3}, Depei Wu^{1

2

3

4}, Yang Xu^{1

2

3

4}

Affiliations

¹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
² Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
³ Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
⁴ State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China.

PMID: 33733985
DOI: 10.1080/10428194.2021.1901095

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / therapeutic use
Guanine / analogs & derivatives
Hematopoietic Stem Cell Transplantation* / adverse effects
Hepatitis B Surface Antigens
Hepatitis B virus
Hepatitis B* / drug therapy
Hepatitis B* / prevention & control
Humans
Immunoglobulins
Lamivudine / therapeutic use
Treatment Outcome

Substances

Antiviral Agents
Hepatitis B Surface Antigens
Immunoglobulins
Lamivudine
entecavir
Guanine
hepatitis B hyperimmune globulin